Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.

导出 OA

翻译打印收藏纠错

作者： Gu,Xiao ^[1] ; George K,Annor ^[2] ; Kimberly,Fung ^[3] ; Outi,Keinänen ^[4] ; Brian M,Zeglis ^[5] ; Jill,Bargonetti ^[6]

作者单位： Department of Biological Sciences Hunter College, City University of New York, New York, New York 10021, United States. ^[1] Department of Biological Sciences Hunter College, City University of New York, New York, New York 10021, United States.;The Graduate Center Biochemistry PhD Program of City University of New York, New York, New York 10016, United States. ^[2] Department of Chemistry Hunter College of the City University of New York, New York, New York 10021, United States.;Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, New York 10016, United States. ^[3] Department of Chemistry Hunter College of the City University of New York, New York, New York 10021, United States. ^[4] Department of Chemistry Hunter College of the City University of New York, New York, New York 10021, United States.;Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, New York 10016, United States.;Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, United States. ^[5] Department of Biological Sciences Hunter College, City University of New York, New York, New York 10021, United States.;The Graduate Center Biochemistry PhD Program of City University of New York, New York, New York 10016, United States.;Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, New York 10021, United States. ^[6]

关键词 TNBC molecular imaging mutant p53 peptides preclinical